Induction Therapy for Lupus Nephritis: the Highlights
- PMID: 30109511
- DOI: 10.1007/s11926-018-0766-9
Induction Therapy for Lupus Nephritis: the Highlights
Abstract
Purpose of review: Lupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN.
Recent findings: Several clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways. At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.
Keywords: Induction therapy; Lupus nephritis; Renal outcome.
Similar articles
-
The safety of pharmacological treatment options for lupus nephritis.Expert Opin Drug Saf. 2016 Aug;15(8):1041-54. doi: 10.1080/14740338.2016.1182496. Epub 2016 May 13. Expert Opin Drug Saf. 2016. PMID: 27159360 Review.
-
Pediatric lupus nephritis: more options, more chances?Lupus. 2013 May;22(6):545-53. doi: 10.1177/0961203313485490. Epub 2013 Apr 29. Lupus. 2013. PMID: 23629826 Review.
-
Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.Pediatr Nephrol. 2005 Oct;20(10):1500-3. doi: 10.1007/s00467-005-1983-9. Epub 2005 Jul 15. Pediatr Nephrol. 2005. PMID: 16021476
-
Pathogenesis and treatment of systemic lupus erythematosus nephritis.Curr Opin Rheumatol. 2006 Sep;18(5):468-75. doi: 10.1097/01.bor.0000240356.45550.13. Curr Opin Rheumatol. 2006. PMID: 16896284 Review.
-
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.Clin J Am Soc Nephrol. 2009 Mar;4(3):579-87. doi: 10.2215/CJN.04030808. Epub 2009 Mar 4. Clin J Am Soc Nephrol. 2009. PMID: 19261822 Free PMC article.
Cited by
-
Lupus nephritis: challenges and progress.Curr Opin Rheumatol. 2019 Nov;31(6):682-688. doi: 10.1097/BOR.0000000000000642. Curr Opin Rheumatol. 2019. PMID: 31389814 Free PMC article. Review.
-
Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients.Clin Rheumatol. 2022 Nov;41(11):3363-3371. doi: 10.1007/s10067-022-06258-0. Epub 2022 Jul 19. Clin Rheumatol. 2022. PMID: 35854166
-
Clinical research progress of novel biologics for the treatment of lupus nephritis.Clin Exp Med. 2023 Dec;23(8):4153-4162. doi: 10.1007/s10238-023-01143-9. Epub 2023 Jul 22. Clin Exp Med. 2023. PMID: 37481481 Review.
-
Effectiveness and safety of tripterygium glycosides tablet for lupus nephritis: a systematic review and Meta-analysis.J Tradit Chin Med. 2022 Oct;42(5):671-680. doi: 10.19852/j.cnki.jtcm.2022.05.001. J Tradit Chin Med. 2022. PMID: 36083472 Free PMC article.
-
Individualizing Therapy in Lupus Nephritis.Kidney Int Rep. 2019 Aug 20;4(10):1366-1372. doi: 10.1016/j.ekir.2019.08.005. eCollection 2019 Oct. Kidney Int Rep. 2019. PMID: 31701046 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials